Search alternatives:
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), clinical areas (Expand Search)
linear decrease » linear increase (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
Showing 1 - 20 results of 5,723 for search '(( significant ((clinical decrease) OR (linear decrease)) ) OR ( significant gap decrease ))', query time: 0.59s Refine Results
  1. 1
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  2. 2
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  3. 3
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  4. 4
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  5. 5
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  6. 6
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  7. 7
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  8. 8
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  9. 9
    The results of linear mixed model.

    The results of linear mixed model. by Soheila Qanbari (20455173)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 10
    Linear relationships (Spearman’s r (p-value)) the treatment-induced changes in clinical and neurophysiological data.

    Linear relationships (Spearman’s r (p-value)) the treatment-induced changes in clinical and neurophysiological data. by Soheila Qanbari (20455173)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 11
    The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin levels: A secondary study from the WHICH randomized clinical trial

    The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin... by Chanel Avenant (409756)

    Published 2025
    “…Any within or between contraceptive group androgenic effects on behavior in the brain are likely dominated by the androgenic activities of MPA and NET and not by the decreased endogenous testosterone levels. The clinical trial was registered with the Pan African Clinical Trials Registry (PACTR 202009758229976)</p>…”
    Save to List
    Saved in:
  12. 12
    The linearly decreasing convergence factor a.

    The linearly decreasing convergence factor a. by Junhao Wei (6816803)

    Published 2025
    Save to List
    Saved in:
  13. 13
    Scatterplot of observed barrier scores against knowledge scores (top) and confidence scores (bottom) with linear line of best fit.

    Scatterplot of observed barrier scores against knowledge scores (top) and confidence scores (bottom) with linear line of best fit. by Lisa Thiele (6468056)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Distribution of responses to vital signs.

    Distribution of responses to vital signs. by Lisa Thiele (6468056)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Survey tool development process.

    Survey tool development process. by Lisa Thiele (6468056)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Respondent characteristics.

    Respondent characteristics. by Lisa Thiele (6468056)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Brain regions with significantly decreased activations for the Raven task are shown in blue.

    Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

    Published 2025
    Save to List
    Saved in:
  18. 18
    Baseline patient characteristics.

    Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Effects of s-ketamine and midazolam on respiratory parameters.

    Effects of s-ketamine and midazolam on respiratory parameters. by Oscar F. C. van den Bosch (22184246)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Flow chart of the study participants.

    Flow chart of the study participants. by Oscar F. C. van den Bosch (22184246)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: